[$$] Gilead Sciences’ Earnings Triple on New Hepatitis Drug

[at The Wall Street Journal] – Gilead Sciences reported nearly $2.3 billion in first-quarter sales for its new hepatitis C treatment Sovaldi in what is believed to be the best-selling prescription drug launch in history. more

View todays social media effects on GILD

View the latest stocks trending across Twitter. Click to view dashboard

See who Gilead is hiring next, click here to view